Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | 217 | Edison Investment Research | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | |
Do | Metlen (ASE: MYTIL) FY24 Results | 159 | Edison Investment Research | Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus... ► Artikel lesen | |
Do | Mendus - Vididencel on track in AML going into 2025 | 163 | Edison Investment Research | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | |
Do | Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results | 225 | Edison Investment Research | Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
BYD | 2.014 |
RHEINMETALL | 1.830 |
RENK GROUP | 1.600 |
NVIDIA | 1.525 |
SUPER MICRO COMPUTER | 1.505 |
TUI | 1.440 |
BAYER | 1.306 |
TESLA | 1.069 |
ALIBABA | 1.042 |
D-WAVE QUANTUM | 995 |
PALANTIR TECHNOLOGIES | 966 |
NOVO NORDISK | 946 |
THYSSENKRUPP | 934 |
EVOTEC | 879 |
PROSIEBENSAT.1 | 806 |
MERCEDES-BENZ | 724 |
BLOCK | 713 |
NEL | 710 |
XIAOMI | 679 |
INTEL | 651 |
NEWMONT | 615 |
PUMA | 581 |
VARTA | 530 |
BASF | 526 |
DEUTSCHE BANK | 520 |